Cita APA

Wood, A., George, S., Adra, N., Chintala, S., Damayanti, N., & Pili, R. (2019). Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Invest New Drugs.

Chicago Style Citation

Wood, Anthony, Saby George, Nabil Adra, Sreenivasulu Chintala, Nur Damayanti, i Roberto Pili. "Phase I Study of the MTOR Inhibitor Everolimus in Combination With the Histone Deacetylase Inhibitor Panobinostat in Patients With Advanced Clear Cell Renal Cell Carcinoma." Invest New Drugs 2019.

Cita MLA

Wood, Anthony, et al. "Phase I Study of the MTOR Inhibitor Everolimus in Combination With the Histone Deacetylase Inhibitor Panobinostat in Patients With Advanced Clear Cell Renal Cell Carcinoma." Invest New Drugs 2019.